Valneva reports a 32.5% year-over-year revenue decline but maintains its 2026 outlook amid geopolitical challenges.
Valneva reported a first-half GAAP loss of €0.35 per share and revenue of €65.84 million, down 32.5% from the same period last year. The company cited ongoing geopolitical pressures affecting travel as a key factor in the decline.
The biotech firm held a cash position of €121.5 million as of June 30, 2026. Despite the revenue drop, Valneva reaffirmed its full-year 2026 guidance, signaling confidence in its financial stability.
No immediate market reaction was disclosed in the release.